Clinical Trial

Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts

Study acronym: APEX-MF
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare momelotinib and ruxolitinib as treatments for myelofibrosis with low blood cell counts. Both drugs are approved by the FDA to treat myelofibrosis. The study asks which drug does a better job at shrinking the spleen.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-25.
Trial Details
NCT Number NCT07498205
Lead Sponsor SWOG Cancer Research Network
Collaborators: GlaxoSmithKline
Conditions Myelofibrosis, Myelofibrosis (MF)
Enrollment 268 participants
Start Date 2026-08-08
Primary Completion 2029-08-08 (estimated)
Study Completion 2031-08-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-05